Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
Authors
Keywords
-
Journal
Cells
Volume 10, Issue 5, Pages 1006
Publisher
MDPI AG
Online
2021-04-25
DOI
10.3390/cells10051006
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy
- (2021) Bin Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Hypoxia and the phenomenon of immune exclusion
- (2021) Violena Pietrobon et al. Journal of Translational Medicine
- Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer
- (2021) Michael Skwarski et al. CLINICAL CANCER RESEARCH
- A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
- (2021) Aparna Hegde et al. CLINICAL CANCER RESEARCH
- Top 10 Challenges in Cancer Immunotherapy
- (2020) Priti S. Hegde et al. IMMUNITY
- Crosstalk Between Hypoxia and ER Stress Response: A Key Regulator of Macrophage Polarization
- (2020) Paula Díaz-Bulnes et al. Frontiers in Immunology
- Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia
- (2020) Sylwia Bartoszewska et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma.
- (2020) Eric Jonasch et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors
- (2020) Curtis David Chin et al. MODERN PATHOLOGY
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions
- (2020) S.V. Liu et al. ANNALS OF ONCOLOGY
- HIF-2α is indispensable for regulatory T cell function
- (2020) Tzu-Sheng Hsu et al. Nature Communications
- Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
- (2020) Adriana Estrada-Bernal et al. CLINICAL CANCER RESEARCH
- Molecular landmarks of tumor hypoxia across cancer types
- (2019) Vinayak Bhandari et al. NATURE GENETICS
- Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints
- (2019) Audrey LEQUEUX et al. CANCER LETTERS
- Targeting hypoxia-induced carbonic anhydrase IX enhances immune checkpoint blockade locally and systemically
- (2019) Shawn C Chafe et al. Cancer Immunology Research
- Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer
- (2019) Jill M. Brooks et al. CLINICAL CANCER RESEARCH
- HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor in Clear Cell Renal Cell Carcinoma Patients
- (2019) Kevin D Courtney et al. CLINICAL CANCER RESEARCH
- Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
- (2019) Annika De Sousa Linhares et al. Scientific Reports
- Hypoxia Regulates Lymphoid Development of Human Hematopoietic Progenitors
- (2019) Sara Chabi et al. Cell Reports
- Relief of tumor hypoxia unleashes the tumoricidal potential of neutrophils
- (2019) Karim Mahiddine et al. JOURNAL OF CLINICAL INVESTIGATION
- Bacteria-Driven Hypoxia Targeting for Combined Biotherapy and Photothermal Therapy
- (2018) Wenfei Chen et al. ACS Nano
- Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy
- (2018) Yiliang Li et al. Frontiers in Immunology
- Targeting adenosine for cancer immunotherapy
- (2018) Robert D. Leone et al. Journal for ImmunoTherapy of Cancer
- Not All Immune Checkpoints Are Created Equal
- (2018) Annika De Sousa Linhares et al. Frontiers in Immunology
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- (2018) Yiyi Yan et al. Frontiers in Immunology
- Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
- (2018) Priyamvada Jayaprakash et al. JOURNAL OF CLINICAL INVESTIGATION
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Tim-3 expression and its role in hepatocellular carcinoma
- (2018) Feifei Liu et al. Journal of Hematology & Oncology
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
- (2017) Emeka K Enwere et al. MODERN PATHOLOGY
- Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma
- (2017) Si-Rui Ma et al. Molecular Cancer
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
- (2017) David Kung-Chun Chiu et al. Nature Communications
- Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
- (2016) Roger M. Phillips CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer
- (2016) Nasim Kheshtchin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Current progress in immunotherapy for pancreatic cancer
- (2016) Kelly Foley et al. CANCER LETTERS
- L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
- (2016) Roger Geiger et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status
- (2016) Yosra Messai et al. EUROPEAN UROLOGY
- Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26
- (2016) David Kung-Chun Chiu et al. HEPATOLOGY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
- (2016) S Chouaib et al. ONCOGENE
- The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
- (2016) Thomas M. Ashton et al. Nature Communications
- Fas ligand and lytic granule differentially control cytotoxic dynamics of natural killer cell against cancer target
- (2016) Yanting Zhu et al. Oncotarget
- Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer
- (2016) Li Ren et al. Oncotarget
- Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
- (2016) Nicole E. Scharping et al. Cancer Immunology Research
- Hypoxia and antitumor CD8+ T cells: An incompatible alliance?
- (2016) Romain Vuillefroy de Silly et al. OncoImmunology
- Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress
- (2016) Alexandra Mowday et al. Cancers
- Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia
- (2015) Muhammad Zaeem Noman et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
- (2015) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Effects of extracellular pH and hypoxia on the function and development of antigen-specific cytotoxic T lymphocytes
- (2015) Yohko Nakagawa et al. IMMUNOLOGY LETTERS
- Hypoxia-Inducible Factor-2 Limits Natural Killer T Cell Cytotoxicity in Renal Ischemia/Reperfusion Injury
- (2015) J. Zhang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Abstract A67: Preclinical efficacy of tarloxotinib bromide (TH-4000), a hypoxia-activated EGFR/HER2 inhibitor: rationale for clinical evaluation in EGFR mutant, T790M-negative NSCLC following progression on EGFR-TKI therapy
- (2015) Shevan Silva et al. MOLECULAR CANCER THERAPEUTICS
- Abstract A66: Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS)
- (2015) Victoria Jackson et al. MOLECULAR CANCER THERAPEUTICS
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological mechanisms of the antitumor effects of supplemental oxygenation
- (2015) Stephen M. Hatfield et al. Science Translational Medicine
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- The Clinical Significance of Hypoxia in Human Cancers
- (2015) Neesha Dhani et al. SEMINARS IN NUCLEAR MEDICINE
- Immune Response Regulation in the Tumor Microenvironment by Hypoxia
- (2015) Sara Labiano et al. SEMINARS IN ONCOLOGY
- Hypoxia and Predicting Radiation Response
- (2015) Richard P. Hill et al. SEMINARS IN RADIATION ONCOLOGY
- T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition
- (2015) R. Houot et al. Cancer Immunology Research
- Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators
- (2015) Stephen M Hatfield et al. OncoImmunology
- Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
- (2014) S R McKeown BRITISH JOURNAL OF RADIOLOGY
- Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
- (2014) M. K. Keck et al. CLINICAL CANCER RESEARCH
- In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
- (2014) K. A. Schalper et al. CLINICAL CANCER RESEARCH
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity
- (2013) Andrea Casazza et al. CANCER CELL
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC
- (2013) Mirna Balsamo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes
- (2013) Markus Duechler et al. IMMUNOBIOLOGY
- Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells
- (2013) Z. Husain et al. JOURNAL OF IMMUNOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Intratumor Hypoxia Promotes Immune Tolerance by Inducing Regulatory T Cells via TGF-β1 in Gastric Cancer
- (2013) Bin Deng et al. PLoS One
- Synthesis of substituted 5-bromomethyl-4-nitroimidazoles and use for the preparation of the hypoxia-selective multikinase inhibitor SN29966
- (2013) Guo-Liang Lu et al. TETRAHEDRON
- Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
- (2013) Christopher P. Guise et al. Chinese Journal of Cancer
- VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
- (2012) N G Gavalas et al. BRITISH JOURNAL OF CANCER
- TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
- (2012) Qian Liu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC)
- (2012) Suzanne Ostrand-Rosenberg et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Abstract A247: Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966.
- (2012) J. B. Smaill et al. MOLECULAR CANCER THERAPEUTICS
- Imaging hypoxia to improve radiotherapy outcome
- (2012) Michael R. Horsman et al. Nature Reviews Clinical Oncology
- The unfolded protein response: controlling cell fate decisions under ER stress and beyond
- (2012) Claudio Hetz NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa
- (2012) E. T. Clambey et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
- (2012) Suzanne Ostrand-Rosenberg et al. SEMINARS IN CANCER BIOLOGY
- Passing the baton: the HIF switch
- (2012) Mei Yee Koh et al. TRENDS IN BIOCHEMICAL SCIENCES
- Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
- (2012) Salem Chouaib et al. Frontiers in Immunology
- Hypoxia Induces Escape from Innate Immunity in Cancer Cells via Increased Expression of ADAM10: Role of Nitric Oxide
- (2011) I. B. Barsoum et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia
- (2011) Tomasz Rzymski et al. CELL CYCLE
- Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
- (2011) J. D. Sun et al. CLINICAL CANCER RESEARCH
- Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features
- (2011) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
- (2011) F. Meng et al. MOLECULAR CANCER THERAPEUTICS
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- In vivo T Cell Activation in Lymphoid Tissues is Inhibited in the Oxygen-Poor Microenvironment
- (2011) Akio Ohta et al. Frontiers in Immunology
- The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3
- (2010) C. P. Guise et al. CANCER RESEARCH
- Macrophage Expression of Hypoxia-Inducible Factor-1 Suppresses T-Cell Function and Promotes Tumor Progression
- (2010) A. L. Doedens et al. CANCER RESEARCH
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
- (2010) Howard L Kaufman et al. Future Oncology
- Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer
- (2010) Johanna Chiche et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation
- (2010) Hongxia Z. Imtiyaz et al. JOURNAL OF CLINICAL INVESTIGATION
- HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
- (2010) Cesar A. Corzo et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
- (2010) Li Yang et al. TRENDS IN IMMUNOLOGY
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- A Distinct Macrophage Population Mediates Metastatic Breast Cancer Cell Extravasation, Establishment and Growth
- (2009) Binzhi Qian et al. PLoS One
- How do Regulatory T Cells Work?
- (2009) A. Corthay SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Divergent effects of hypoxia on dendritic cell functions
- (2008) A. Mancino et al. BLOOD
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
- (2008) T. Azuma et al. BLOOD
- The tumor microenvironment and metastatic disease
- (2008) Sarah Jane Lunt et al. CLINICAL & EXPERIMENTAL METASTASIS
- Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus
- (2008) Manish K Aghi et al. MOLECULAR THERAPY
- Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?
- (2008) Daniel T. Bergstralh et al. TRENDS IN GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search